Barclays
OTLK icon

Barclays’s Outlook Therapeutics OTLK Stock Holding History

Barclays’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1
Closed -$2 – 5323
2025
Q4 		$2 Hold
1
– – ﹤0.01% 5181
2025
Q3 		$1 Sell
1
-100
-99% -$173 ﹤0.01% 5450
2025
Q2 		$162 Sell
101
-16,939
-99% -$27K ﹤0.01% 5096
2025
Q1 		$20.8K Sell
17,040
-6,840
-29% -$12K ﹤0.01% 4786
2024
Q4 		$45.1K Buy
23,880
+2,937
+14% +$12.1K ﹤0.01% 4781
2024
Q3 		$112K Buy
20,943
+18,249
+677% +$134K ﹤0.01% 4539
2024
Q2 		$19.9K Sell
2,694
-2,802
-51% -$22.5K ﹤0.01% 4438
2024
Q1 		$65.6K Sell
5,496
-5,299
-49% -$42.8K ﹤0.01% 4558
2023
Q4 		$85.1K Buy
10,795
+9,447
+701% +$79.9K ﹤0.01% 4673
2023
Q3 		$5.96K Sell
1,348
-200
-13% -$4.42K ﹤0.01% 4367
2023
Q2 		$53.9K Sell
1,548
-2,412
-61% -$65.8K ﹤0.01% 3808
2023
Q1 		$86.3K Buy
3,960
+2,370
+149% +$53K ﹤0.01% 4258
2022
Q4 		$34.4K Buy
1,590
+1,339
+533% +$29.1K ﹤0.01% 4674
2022
Q3 		$6K Sell
251
-46
-15% -$1.07K ﹤0.01% 4467
2022
Q2 		$6K Sell
297
-628
-68% -$18.1K ﹤0.01% 4752
2022
Q1 		$32K Sell
925
-4,480
-83% -$140K ﹤0.01% 4288
2021
Q4 		$147K Buy
5,405
+3,585
+197% +$128K ﹤0.01% 3643
2021
Q3 		$79K Buy
1,820
+969
+114% +$46.8K ﹤0.01% 3991
2021
Q2 		$42K Buy
851
+382
+81% +$17.7K ﹤0.01% 4212
2021
Q1 		$21K Buy
+469
New +$18K ﹤0.01% 4360
2020
Q2 		– Sell
-1,761
Closed -$21K – 6077
2020
Q1 		$21K Hold
1,761
– – ﹤0.01% 5627
2019
Q4 		$21K Buy
+1,761
New +$41K ﹤0.01% 5975
2019
Q2 		– Sell
-1
Closed – – 7160
2019
Q1 		$0 Buy
+1
New +$141 ﹤0.01% 7239

Other funds holding OTLK

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $126M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NMC
Nine Masts Capital Central, Hong Kong $693M AUM 31.93% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return

Barclays's OTLK Position: Q1 2026 in Review

Barclays sold out of Outlook Therapeutics (OTLK) in Q1 2026, closing a stake of 1 share — an estimated $2 sold.

Barclays first reported a position in OTLK in Q1 2019 and held it in 23 quarters. The position peaked at $147K in Q4 2021. 54 funds tracked by Wall St. Rank hold OTLK as of Q1 2026.

  • Barclays reported no remaining Outlook Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Barclays sold 1 Outlook Therapeutics share in Q1 2026, an estimated $2.
  • Barclays first reported a position in Outlook Therapeutics in Q1 2019 and held it in 23 quarters.
  • Barclays's Outlook Therapeutics position peaked at $147K in Q4 2021.
  • 54 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.